Xeris Biopharma Holdings, Inc. (XERS) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Xeris Biopharma Holdings, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | 2273.17x | -9.07x | -5.20x | -1.91x | -1.89x | -2.30x |
| P/B Ratio | 92.00x | -16.80x | -47.71x | 3.99x | 2.43x | 6.21x |
| P/S Ratio | 4.32x | 2.45x | 1.97x | 1.64x | 4.67x | 10.27x |
| Profitability | ||||||
| Gross Margin | 81.7% | 81.9% | 82.5% | 79.5% | 73.1% | 54.4% |
| Operating Margin | 8.5% | -16.6% | -26.8% | -74.3% | -232.2% | -408.8% |
| Net Margin | 0.2% | -27.0% | -38.0% | -85.9% | -247.5% | -446.0% |
| EBITDA Margin | 4.4% | -6.9% | -14.5% | -62.9% | -229.2% | -387.2% |
| Liquidity | ||||||
| Current Ratio | 2.19x | 1.67x | 1.64x | 2.54x | 1.80x | 5.40x |
| Quick Ratio | 1.57x | 1.19x | 1.23x | 2.20x | 1.57x | 5.10x |
| Leverage | ||||||
| Debt/Equity | 2.76x | -9.17x | -33.79x | 4.38x | 0.92x | 2.58x |
YoY = year-over-year change. Source: FMP..